Results 61 to 70 of about 5,903 (227)

Effects of Natural Health Products in Combination with FP-Based Chemotherapy

Pharmaceuticals
Background: Cancer patients often use natural health products (NHPs) during chemotherapy without medical supervision. We have previously described the clinical cases of two patients taking capecitabine in combination with folate supplements who suffered ...
Valeria Conti, Berenice Stefanelli, Carmineantonio Romeo, Alessandra De Stefano, Dominga Valentino, Graziamaria Corbi, Francesco Sabbatino, Emanuela De Bellis, Amelia Filippelli   +8 more
doaj   +1 more source

Longitudinal AMH trajectories, ovarian reserve recovery, and fertility outcomes after multiagent chemotherapy for high‐risk gestational trophoblastic neoplasia: A real‐world cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To characterize anti‐Müllerian hormone (AMH) recovery after multiagent chemotherapy for high‐risk gestational trophoblastic neoplasia (GTN) and evaluate the impact of regimen and hysterectomy. Methods This was a retrospective cohort of 68 high‐risk GTN patients treated with EMA/CO (etoposide, methotrexate, actinomycin D ...
Wei Xue, Tianyi Chen, Yuxiao Wu, Tong Ren, Jun Zhao, Fengzhi Feng, Xirun Wan, Yang Xiang, Junjun Yang   +8 more
wiley   +1 more source

Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase

, 2019
Fluoropyrimidines are widely used in the treatment of solid tumors, mainly gastrointestinal, head and neck and breast cancer. Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme for catabolism of 5-FU and it is encoded by DPYD gene. To date,
Ranallo N., Merloni F., Scortichini L., Giampieri R., Berardi R.   +4 more
core   +2 more sources

Contemporary Treatment Patterns in Surgically Treated Temporal Bone Cancer

The Laryngoscope, EarlyView.
In a national cohort of 811 surgically treated temporal bone cancer patients, adjuvant radiation therapy was the most frequently utilized postoperative treatment (20.3%), while chemotherapy and immunotherapy were used far less frequently. Multimodal treatment, particularly combined parotidectomy and neck dissection, was strongly associated with higher ...
Raquel Rowell, Christopher Z. Wen, Vera Bzhilyanskaya, Jane Y. Tong, Adam C. Kaufman   +4 more
wiley   +1 more source

Retrospective UK analysis of dihydropyrimidine dehydrogenase (DPYD)gene testing, toxicity and ethnicity for patients receiving Fluoropyrimidines(5-fluorouracil, capecitabine and tegafur) - National Transformation Project from the NHS Genomic Medicine Service Alliances (GMSAs)

, 2023
Retrospective UK analysis of dihydropyrimidine dehydrogenase (DPYD) gene testing, toxicity and ethnicity for patients receiving Fluoropyrimidines (5-fluorouracil, capecitabine and tegafur) - National Transformation Project from the NHS Genomic Medicine ...
Aris Saoulidis (8397075)
core   +1 more source

Schisandrin C Targets PPARγ to Induce Ferroptosis in Colorectal Cancer Cells and Promote M1 Macrophage Polarization

Phytotherapy Research, EarlyView.
Schisandrin C: A Dual Anti‐Colorectal Cancer Strategy Targeting PPARγ. ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer mortality, necessitating novel therapeutic strategies. Schisandrin C (SinC), a bioactive lignan from Schisandra chinensis, exhibits diverse pharmacological activities, but its anti‐CRC mechanisms are poorly ...
Xiao Wei, Hong‐Ping Wen, Jian‐Bo Song, Jin‐Fang Xu, Hong‐Rui Guo   +4 more
wiley   +1 more source

Seven Years of Watch and Wait With Rectal Cancer—Reflections and Optimisations

ANZ Journal of Surgery, EarlyView.
ABSTRACT Purpose Sir Charles Gairdner Hospital (SCGH) commenced an observation strategy in patients with a complete clinical response, Watch and Wait (W&W), for rectal adenocarcinoma in 2017 using a rigorous surveillance protocol. Our earlier results (2017–2019) have been published.
Ben Finlay, Emma Powell, Anne Long, Rohen White, John Herron, Michael Warner   +5 more
wiley   +1 more source

Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer

npj Breast Cancer, 2021
Triple-negative breast cancer (TNBC) remains the most lethal breast cancer subtype with poor response rates to the current chemotherapies and a lack of additional effective treatment options.
Craig Davison, Roisin Morelli, Catherine Knowlson, Melanie McKechnie, Robbie Carson, Xanthi Stachtea, Kylie A. McLaughlin, Vivien E. Prise, Kienan Savage, Richard H. Wilson, Karl A. Mulligan, Peter M. Wilson, Robert D. Ladner, Melissa J. LaBonte   +13 more
doaj   +1 more source

Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial. [PDF]

Cardiooncology
Background Fluoropyrimidines (FP) are the third most used chemotherapeutic drugs administered in solid tumors but have cardiotoxic side effects. We aimed to determine whether pre-chemotherapeutic cardiological assessment and management of cardiovascular ...
Lyhne JD, Hansen VB, Vestergaard LD, Hosbond SE, Busk M, Gnanaganesh M, Maae E, Havelund BM, Hansen TF, Timm S, Jensen LH, Lyhne MD.   +11 more
europepmc   +2 more sources

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

British Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen, Ines Bentahrour, Camille Guerin, Charles Dolladille, Angélique Da Silva, François Cherifi, Elise‐Marie Minoc, Pierre‐Marie Morice, Nicolas Jacquin, Christophe Le Tourneau, Joachim Alexandre, Ahmad Nehme, Etienne Bastien   +12 more
wiley   +1 more source